



Pyoderma Gangrenosum: A Case Report

Figilo Ibeinmo Moses^{a,b*}, Dasetima D. Altraide^a, Amaewhule Mary Nnenda^a, Amadi Ekechi Stella^a, Ajirenike Rita Nkiru^a, Chikeka Chimaroke Ukachi^a and Ogbu Christian^a

^a River State University Teaching Hospital, Harley Street, Old G.R.A Port-Harcourt, Rivers State, Nigeria.

^b Federal Medical Centre, Yenagoa, Bayelsa State, Nigeria.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/112919>

Case Study

Received: 15/02/2024

Accepted: 17/04/2024

Published: 24/04/2024

ABSTRACT

Pyoderma Gangrenosum (PG) is an Uncommon Neutrophilic Dermatoses that presents as Auto-Inflammatory and Ulcerative Disorder of the Skin. It has an estimated incidence of 3-10 cases per million people per year. It is more common in the young and middle-aged people, average age of onset- 40-60years, although it can affect children. It has female preponderance, and is characterized by painful papule, plaque or pustule that rapidly ulcerate with raised undermined borders on sites of normal or traumatized skin. It has no pathognomonic diagnostic test.

Keywords: pyoderma gangrenosum; neutrophilic dermatoses; auto-inflammatory; pathognomonic.

*Corresponding author: E-mail: figilomoses@yahoo.com;

1. INTRODUCTION

Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis that presents as an inflammatory, painful, ulcerative disorder of the skin [1].

In contrast to its name, PG is neither an infectious nor gangrenous condition [1].

Due to neutrophil dysfunction, genetic susceptibility and systemic inflammation [1].

2. CASE PRESENTATION

A 67 year old Rheumatoid arthritic and Hypertensive patient of 38 and 15 years duration respectively, with poor drug adherence, who presented to the accident and emergency department of the Rivers State University Teaching Hospital (RSUTH) due to complaints of painful right leg ulcers of 1 week duration [2-4].

Had trauma to the affected limb, few days prior to the onset of ulcers.

No complaints of intermitent claudication, progressive weight loss.

Known to be living with hypertension for 15 years and rheumatoid arthritis for 38 years and on medications though not adherent (metformin, glimepiride, amlodipine, candesartan, hydroxychloroquine, prednisolone) [5-8].

On examination revealed an elderly woman, in obvious painful distress, febrile (38C), not pale, anicteric, not cyanosed, not dehydrated, nil palpable peripheral lymphadenopathy, rheumatoid nodules, swan neck and boutonniere deformities of the fingers of both hands, bilateral pitting lower limb edema right > left, with two ulcers on the medial aspect of the shin and ankle of the right leg [9-14,15-17].

2 oval shaped ulcers, located over the medial aspect of the right shin and ankle, with necrotic floor with slough, with differential warmth, tender, measuring 4cm-length,4cm-width,0.5cm-depth, undermined edges and raised borders [18,19].

Dorsalis pedis and posterior tibialis pulses were diminished.

No regional lymphadenopathy.

No abnormalities of the hairs and nails.



Fig. 1. Morphological identification mark



Fig. 2. Systemic therapy

Investigations revealed moderate growth of staphylococcus aureus sensitive to moxifloxacin on wound swab microscopy, culture and sensitivity test. Punch skin biopsy of the ulcer showed focal area of ulceration on the epithelium, beneath the epithelium contained mixed inflammatory cells infiltrate, predominantly neutrophils with necrotic tissues and hemorrhage [20-22]. Complete blood count revealed anemia, other parameters were within normal range. A

diagnosis of pyoderma gangrenosum (PG) on background rheumatoid arthritis and hypertension was made. She was counseled on the nature of the disease and commenced on treatment.

Systemic therapy with tabs. prednisolone 30mg daily and topical clobetasol cream, caps. tramadol 50mg, tabs.zinc 50mg daily.

Patient made significant clinical improvement and was discharged but failed to follow up at clinic.

3. DISCUSSION

Pyoderma gangrenosum is a rare, neutrophil-mediated, auto-inflammatory dermatosis that is characterized by painful, necrotic ulceration.

Due to neutrophil dysfunction, genetic susceptibility and systemic inflammation.

Commonly presents as a nodule, plaque or pustule that rapidly develops into a painful, purulent ulcer with raised undermined borders on sites of normal or traumatized skin.

Clinically has 4 variants; ulcerative (classic), bullous, pustular, vegetative.

It is associated with pathergy in 25%, systemic diseases in 50% of cases.

It is associated with inflammatory bowel disease, inflammatory arthritis, hematological neoplasms, and some clinical syndromes;

- * PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne) syndrome.
- * PAPASH (pyogenic arthritis, pyoderma gangrenosum, acne, and suppurative hidradenitis) syndrome.
- * PASH (pyoderma gangrenosum, acne, and suppurative hidradenitis) syndrome.

Diagnosis is made with the help of biopsy of the lesions, in addition to other clinical signs (pathergy, rapid expansion of the lesions).

Treatment is largely aimed at reducing inflammation, controlling pain, promoting wound re-epithelization, and treating the underlying etiology.

Treatment modalities include: Immunosuppressive therapy, biologics, alkylating agents, corticosteroid (topical, systemic), intravenous Immunoglobulins.

4. CONCLUSION

Pyoderma gangrenosum is a rare, neutrophil-mediated, auto-inflammatory dermatosis that is characterized by painful, necrotic ulceration. There is no specific diagnostic test, hence it is often mis-diagnosed, and under-

reported. It can be treated using, Immunosuppressive therapy, biologics, alkylating agents, corticosteroid (topical, systemic), intravenous Immunoglobulins.

CONSENT

Written consent was collected and preserved by the authors.

ETHICAL APPROVAL

As per international standards or university standards written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. DeFilippis EM, Feldman SR, Huang WW. The Genetics of Pyoderma Gangrenosum and Implications for Treatment: A Systematic Review. *Br J Dermatol*; 2014
2. Branagan NM, Higgins SP, Halim SA, Le TH. Systemic polyarteritis nodosa mimicking pyoderma gangrenosum in a rare association with small lymphocytic leukaemia/chronic lymphocytic leukaemia. *Clin Exp Dermatol*. 2009;34(5): e127-9.
3. Namazi MR, Kerchner KR, Pichardo RO. Essential type II mixed cryoglobulinemia causing pyoderma gangrenosum-like ulcers. *Scientific World Journal*. 2008;8:228.
4. Vadillo M, Jucgla A, Podzamczar D, Rufi G, Domingo A. Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia. *Br J Dermatol*. 1999;141(3): 541-3.
5. González-Moreno J, Ruíz-Ruigomez M, Callejas Rubio J, Ríos Fernández R, Ortego Centeno N. Pyoderma gangrenosum and systemic lupus erythematosus: A report of five cases and review of the literature. *Lupus*; 2014.
6. Ashchyan HJ, Butler DC, Nelson CA, Noe MH, Tsiaras WG, Lockwood SJ, et al. The Association of age with Clinical Presentation and Comorbidities of

- Pyoderma Gangrenosum. JAMA Dermatol. 2018;154(4):409-413.
7. Brown TS, Marshall GS, Callen JP. Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum: a rarely recognized extracutaneous manifestation of a neutrophilic dermatosis. J Am Acad Dermatol. 2000;43(1 Pt 1):108-12.
 8. Ayyala RS, Armstrong S. Corneal melting and scleromalacia perforans in a patient with pyoderma gangrenosum and acute myeloid leukemia. Ophthalmic Surg Lasers. 1998;29(4):328-31.
 9. Happle R, Schiffer HP, Kövary PM. Ocular involvement in pyoderma gangrenosum. Arch Dermatol. 1977 113 (11):1612.
 10. Ashchyan HJ, Nelson CA, Stephen S, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses. Part II. Pyoderma gangrenosum and other bowel and arthritis associated neutrophilic dermatoses. J Am Acad Dermatol; 2018.
 11. Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011; 165(6):1244-50.
 12. Graham JA, Hansen KK, Rabinowitz LG, Esterly NB. Pyoderma gangrenosum in infants and children. Pediatr Dermatol. 1994;11(1):10-7.
 13. Schoemann MB, Zenn MR. Pyoderma gangrenosum following free transverse rectus abdominis myocutaneous breast reconstruction: A case report. Ann Plast Surg. 2010;64(2):151-4.
 14. Rietjens M, Cuccia G, Brenelli F, Manconi A, Martella S, De Lorenzi F. A Pyoderma Gangrenosum Following Breast Reconstruction: A Rare Cause of Skin Necrosis. Breast J; 2009.
 15. Nybaek H, Olsen AG, Karlsmark T, Jemec GB. Topical therapy for peristomal pyoderma gangrenosum. J Cutan Med Surg. 2004;8(4):220-3.
 16. Jackson JM. TNF- alpha inhibitors. Dermatol Ther. 2007;20(4):251-64.
 17. Fedi MC, Quercetani R, Lotti T. Recalcitrant pyoderma gangrenosum responsive to cyclosporine. Int J Dermatol. 1993;32(2):119.
 18. Ahmad K, Ramsay B. Pyoderma gangrenosum associated with subcorneal pustular dermatosis and IgA myeloma. Clin Exp Dermatol. 2009;34(1): 46-8.
 19. McCalmont CS, Leshin B, White WL, Greiss FC Jr, Jorizzo JL. Vulvar pyoderma gangrenosum. Int J Gynaecol Obstet. 1991;35(2):175-8.
 20. Ho SA, Tan WP, Tan AW, Wong SN, Chua SH. Scrotal pyoderma gangrenosum associated with Crohn's disease. Singapore Med J. 2009;50(12):e397-400.
 21. Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med. 2002;347 (18):1412-8.
 22. Fathalla BM, Al-Wahadneh AM, Al-Mutawa M, Kambouris M, El-Shanti H. A novel de novo PSTPIP1 mutation in a boy with pyogenic arthritis, pyoderma gangrenosum, acne (PAPA) syndrome. Clin Exp Rheumatol; 2014.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/112919>